title: [Expression of indoleamine 2, 3-dioxygenase and its correlation with prognosis in breast cancer patients].
abstract: OBJECTIVE
  To investigate the expression of indoleamine 2, 3-dioxygenase (IDO) in breast cancer and its correlation with clinicopathologic factors and prognosis.
  
  
  METHODS
  The expression of IDO, CD31, CD105 proteins in 40 specimens of breast cancer were assessed by immunohistochemistry.
  
  
  RESULTS
  The overexpression rate of IDO in breast cancer was 67.5% (27/40), and expression of IDO was closely associated with clinical stage and lymph nodes metastasis. The disease-free survival rate in patients with IDO overexpression was not significantly lower than that in patients with negative or low expression of IDO (P > 0.05). Moreover, the expression of IDO was positively correlated with CD105-labeled microvessel density (r = 0.659, P < 0.05).
  
  
  CONCLUSIONS
  Expression of IDO is associated with clinical stage and lymph nodes metastasis, and microvessel densitty. IDO expression may promote the growth and metastasis of breast cancer, probably via the increased agiogenesis. A larger sample study is needed to verify whether the prognosis of beast cancer is significantly correlated with IDO expression.
authors.affiliation: Hospital of Tianjin Medical University, Tianjin, China.
authors.forename: Jun-tian
authors.initials: JT
authors.lastname: Liu
authors.forename: Li-juan
authors.initials: LJ
authors.lastname: Wei
authors.forename: Jin-pu
authors.initials: JP
authors.lastname: Yu
authors.forename: Hui
authors.initials: H
authors.lastname: Li
authors.forename: Run-mei
authors.initials: RM
authors.lastname: Li
authors.forename: Feng-lin
authors.initials: FL
authors.lastname: Zang
authors.forename: Jing-yan
authors.initials: JY
authors.lastname: Sun
authors.forename: Xiu-bao
authors.initials: XB
authors.lastname: Ren
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology / Q000276:immunology / Q000473:pathology; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000378:metabolism; D001943:Breast Neoplasms / Q000201:enzymology* / Q000276:immunology / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000201:enzymology* / Q000276:immunology / Q000473:pathology; D018276:Carcinoma, Medullary / Q000201:enzymology / Q000276:immunology / Q000473:pathology; D018572:Disease-Free Survival; D000071063:Endoglin; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000378:metabolism*; D008207:Lymphatic Metastasis; D055806:Microvessels / Q000201:enzymology / Q000276:immunology; D008875:Middle Aged; D009367:Neoplasm Staging; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000378:metabolism; D015996:Survival Rate
chemical_list: D015703:Antigens, CD; C064206:ENG protein, human; D000071063:Endoglin; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D011956:Receptors, Cell Surface